Re: Exelixis Announces Initiation of CONTACT-02 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Castration-Resistant Prostate Cancer
Solid market response to this announcement, a couple of things do stand out.
First, all partners are invested.
"The trial is sponsored by Exelixis and co-funded by Roche, Ipsen and Takeda Pharmaceutical Company Limited. "
Second, the launching of the trial confirms that all data including the newest cohorts added to Cosmic 021 continues to be compelling. Some investors may have been waiting to see more data. This announcement pretty much derisks any concern the data may not have held up with more patients and more time.